Equities research analysts expect CTI BioPharma Corp (NASDAQ:CTIC) to announce earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for CTI BioPharma’s earnings, with estimates ranging from ($0.32) to ($0.23). CTI BioPharma posted earnings per share of ($0.30) in the same quarter last year, which suggests a positive year over year growth rate of 6.7%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 6th.

On average, analysts expect that CTI BioPharma will report full year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.91) to ($0.78). For the next year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.09) to ($0.74). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for CTI BioPharma.

CTI BioPharma (NASDAQ:CTIC) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.06). CTI BioPharma had a negative net margin of 361.97% and a negative return on equity of 85.84%. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.60 million.

Several analysts have recently commented on CTIC shares. reissued a “buy” rating and set a $4.00 price target on shares of CTI BioPharma in a research note on Monday, October 1st. Oppenheimer set a $4.00 price target on shares of CTI BioPharma and gave the company a “buy” rating in a research note on Friday, November 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $5.50.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Stonepine Capital Management LLC raised its holdings in CTI BioPharma by 30.9% during the third quarter. Stonepine Capital Management LLC now owns 5,302,063 shares of the biopharmaceutical company’s stock worth $11,452,000 after buying an additional 1,252,765 shares during the last quarter. Opaleye Management Inc. raised its holdings in CTI BioPharma by 860.3% during the third quarter. Opaleye Management Inc. now owns 1,550,000 shares of the biopharmaceutical company’s stock worth $3,348,000 after buying an additional 1,388,600 shares during the last quarter. Algert Global LLC raised its holdings in CTI BioPharma by 55.6% during the third quarter. Algert Global LLC now owns 339,349 shares of the biopharmaceutical company’s stock worth $733,000 after buying an additional 121,326 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in CTI BioPharma by 68.1% during the third quarter. JPMorgan Chase & Co. now owns 568,732 shares of the biopharmaceutical company’s stock worth $1,229,000 after buying an additional 230,386 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in CTI BioPharma by 2.9% during the third quarter. BlackRock Inc. now owns 2,884,361 shares of the biopharmaceutical company’s stock worth $6,230,000 after buying an additional 81,179 shares during the last quarter. Institutional investors and hedge funds own 61.21% of the company’s stock.

CTIC opened at $1.01 on Friday. CTI BioPharma has a one year low of $1.01 and a one year high of $5.36. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.20. The company has a market cap of $64.37 million, a PE ratio of -0.81 and a beta of -0.43.

CTI BioPharma Company Profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Recommended Story: What are retained earnings?

Get a free copy of the Zacks research report on CTI BioPharma (CTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.